Chemomab Therapeutics (CMMB) Operating Expenses (2017 - 2025)

Chemomab Therapeutics (CMMB) has 9 years of Operating Expenses data on file, last reported at $2.0 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses fell 38.56% year-over-year to $2.0 million; the trailing twelve-month figure through Dec 2025 stood at $9.6 million (down 35.09% YoY), and the FY2025 full-year result was $9.6 million, down 35.09% from the prior year.
• Operating Expenses for Q4 2025 stood at $2.0 million, up from $1.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $9.0 million in Q1 2023 and bottomed at $1.7 million in Q1 2021.
• The 5-year median for Operating Expenses is $3.8 million (2023), against an average of $4.5 million.
• The widest annual swing landed in 2022, when Operating Expenses soared 213.13%; it then slumped 55.47% in 2023.
• A 5-year view of Operating Expenses shows it stood at $5.0 million in 2021, then soared by 72.01% to $8.6 million in 2022, then slumped by 55.47% to $3.8 million in 2023, then retreated by 16.5% to $3.2 million in 2024, then sank by 38.56% to $2.0 million in 2025.
• The last three Operating Expenses figures came in at $2.0 million (Q4 2025), $1.8 million (Q3 2025), and $2.3 million (Q2 2025), per Business Quant data.

Peer Comparison